Details of Drug-Drug Interaction
| Drug General Information (ID: DDICY6TFZN) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Ranitidine | Drug Info | Procainamide | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antiulcer Agents | Antiarrhythmic Agents | |||||||
| Structure | |||||||||
| Mechanism of Ranitidine-Procainamide Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Competitive inhibition of renal tubular secretion Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Ranitidine | Procainamide | |||||||
| Mechanism | Competitive inhibition of renal tubular secretion of procainamide | Procainamide | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Renal tubular secretion | ||||||||
| Factor Description | Renal tubular secretion allows selective transfer of substances from the blood around the capillaries into the renal tubules via filtrate. Drug excretion may be reduced when two drugs compete for renal tubular secretion. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Until more information is available, caution is advised when prescribing procainamide with high dosages of ranitidine such as those used in the treatment of Zollinger-Ellison syndrome. In addition, caution may be advisable in certain patient populations such as the elderly or those with liver disease who may experience elevated ranitidine levels at lower dosages. If an interaction is suspected, a dosage adjustment for procainamide or a switch to famotidine or nizatidine may be considered. | ||||||||